Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020

IMPORTANCE: Of approximately 9 million patients with cancer in China in 2020, more than half were diagnosed with late-stage cancers. Recent regulatory reforms in China have focused on improving the availability of new cancer drugs. However, evidence on the clinical benefits of new cancer therapies a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yichen, Naci, Huseyin, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen, Guan, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366546/
https://www.ncbi.nlm.nih.gov/pubmed/35947385
http://dx.doi.org/10.1001/jamanetworkopen.2022.25973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366546/
https://www.ncbi.nlm.nih.gov/pubmed/35947385
http://dx.doi.org/10.1001/jamanetworkopen.2022.25973

Ejemplares similares